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Figure S1. (left) The design of the two-layered SCBC device. The annotations of the valves are 
labeled on the top. (right) The microscopy image of individual cell chambers showing 0, 1, 2 and 
3 cells trapped in a chamber. 
 
Figure S2. The layout of the DNA barcode patterning. The zoom-in picture shows a typical 
validation result of patterned DNA through Cy3-labeled complementary DNA hybridization. 
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Figure S3. Synthetic scheme of GSH-AF647. The thiol group on the GSH molecule reacts with 
AF647-maleimide to afford the product. Modification on other sites such as the amine group and 
the carboxyl groups interfered with antibody binding.  
 
Figure S4. Synthetic scheme of Gluc-Bio. Biotin was linked to glucosamine through HATU 
coupling. The product is a mixture of α-/β- isomers. 
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Figure S5. The effect of high glucose concentration and low temperature on the uptake rate of 
Gluc-Bio. Results prove that the uptake of Gluc-Bio is through the same mechanism as that of 
glucose. 
 
Figure S6. (a) The coupled enzyme reactions allow the assay of hexokinase activities through 
measuring the absorption of NADH. (b) The generation of NADH is much slower with the 
existence of Gluc-Bio. (c) The final amount of NADH is decreased with Gluc-Bio addition. 
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Figure S7. Synthetic scheme of Biotin-BHQ2. The Biotin-Lys-Lys-BHQ2 backbone was prepared 
through solid state peptide synthesis. The PEG motif was attached to the lysine side chain in 
solution. The PEG part is essential for enhancing the solubility of Biotin-BHQ2 and minimizing 
non-specific bindings. 
 
Figure S8. Kinetic immunofluorescence assay results for selective enzymes and metabolites from 
the GBM39 cells treated with 1 μM of erlotinib. The consistent kinetics of Gluc-Bio uptake and 
hexokinase 2 confirms that Gluo-Bio is a substrate for hexokinase. 
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Figure S9. Comparison of metabolite concentrations generated from the immunofluorescence 
assay used in this work (red traces) and from commercially available assay kits (blue traces. 
Glutathione Assay Kit, Cayman Chemical #703002; Cyclic AMP XP Assay Kit, Cell Signaling 
#4339; Cyclic GMP XP Assay Kit, Cell Signaling #4360). These assays utilized the same GBM39 
cells and treatments as were performed Figure S8. 
 
Figure S10. Comparison of signals from 1, 2 and 3 cells generated from the control GBM39 SCBC 
data. The increasing signal with increased cell number demonstrates the validity of the SCBC 
assay. 
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Figure S11.  Unsupervised clustering of SCBC data collected from GBM39 neurosphere tumor 
models before (a) and following treatment with an EGFR inhibitor (b). The right panels show the 
feature of centroids for each population. 
 
Figure S12. Representative 18F-FDG PET/CT images of GBM39 subcutaneous tumor bearing 
mice at 0 or 24 hours post treatment with erlotinib (50m/kg, n=4 mice) for 24 hours. 
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Table S1. DNA sequences used in this work. 
 
 
Table S2. List of capture antibodies and their manufactures used in this work. The corresponding 
DNA names for DEAL conjugation is also provided. 
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Table S3. List of detection antibodies used in this work. 
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Chemicals and Reagents 
Reduced L-glutathione (GSH, 98%), tris(2-carboxyethyl)phosphine hydrochloride (TCEP, 98%), 
biotin (99%), glucosamine hydrochloride (99%), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU, 97%), N,N-diisopropylethylamine 
(DIEA, 99%), citric acid (99.5%), sodium azide (99.5%), N-methyl-2-pyrrolidone (NMP, 99%), 
trifluoroacetic acid (TFA, 99%), triethylsilane (99%), piperidine (99.5%) and glucose assay kit 
(GAHK-20) were purchased from Sigma Aldrich (St. Louis, MO). Phosphate buffered saline was 
purchased from IrvineScientific (Santa Ana, CA). Alexa Fluor 647 C2-Maleimide (AF647-Mal) and 
Alexa Fluor 647 NHS ester (AF647-NHS) were purchased from Life Technologies (Grand Island, 
NY). cAMP-HRP and cGMP-HRP conjugates were purchased from GeneScript (Piscataway, NJ). 
Methanol, dichloromethane, ethyl ether, deionized water and HPLC-grade acetonitrile were 
purchased from VWR (Radnor, PA). Succinimidyl 4-hydrazinonicotinate acetone hydrazine (S-
HyNic), succinimidyl 4-formylbenzoate (S-4FB) and anhydrous N,N-dimtheylformamide (DMF) 
were purchased from Solulink (San Diego, CA). Biotin NovaTagTM resin, Fmoc-Lys(Boc)-OH, 
Fmoc-NH-(PEG)4-COOH were purchased from Millipore (Temecula, CA). BHQ-2 carboxylic acid 
was obtained from Biosearch Technologies (Petaluma, CA) 
Synthetic procedures 
Glutathione-AlexaFluor 647 (GSH-AF647) The synthetic scheme of GSH-AF647 is shown in 
Fig S3. 100 uL of 10 mM reduced glutathione in 1X PBS was mixed with 10 uL of 100 mM TCEP 
in 1X PBS and the solution was shaked at room temperature for 1 hr. Subsequently, 100 uL of 
AF647-Mal (10 mM, in DMSO) was added to the solution and the mixture was shaked in dark at 
room temperature for 2 hours. The crude was separated using reverse-phase HPLC (C18 column, 
A:H2O, B:CH3CN, 100%A to 30%A). The fractions were collected and lyophilized. The product 
was characterized by mass spec (MOLDI-TOF, [M+H+K]2+ calculated: 656.635, observed: 
656.433). 
 
Glucose-biotin (Gluc-Bio) The synthesis of Gluc-Bio is shown in Fig S4. In a typical synthesis, 
270 mg of biotin was dissolved in 30 mL of methanol and 2 mL of N,N-diisopropylethylamine. 380 
mg of HATU was added into the solution and thoroughly mixed. In another flask, 215 mg of 2-
glucosamine hydrochloride was suspended in 5 mL deionized water. This suspension was mixed 
with the biotin/HATU solution and stirred at room temperature for 3 hr. After removing the solvent 
under vacuum, the crude was mixed with 5 mL of water. The resulting mixture was filtered and 
the supernatant was purified using HPLC (C18 column, A:H2O, B:CH3CN, 100%A to 50%A). The 
product was characterized by mass spec (MOLDI-TOF, [M+Na]+ calculated: 428.147, observed: 
428.289). 
 
Biotin-BHQ2 The synthesis of Biotin-BHQ2 was based on the solid state peptide synthesis 
technique. The synthetic scheme is shown in Fig S7. 100 mg of Biotin-NovaTagTM resin was 
suspended in 5 mL of NMP for 2 hr, and then treated with piperidine (5 mL and 10 min, repeat 3 
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times) to perform Fmoc-deprotection. The resin was then washed with 5 mL of NMP (20% in NMP) 
and resuspended in 1 mL of NMP. HATU (0.2 M in NMP, 2 mL), Fmoc-Lys(Boc)-OH (0.2 M in 
NMP, 2 mL) and DIEA (0.5 mL) were added and the mixture was incubated at room temperature 
for 1 hour. The solvent was then removed and the resin was washed with NMP (5 mL) for 3 times. 
Similar synthetic steps were carried out twice to attach another Fmoc-Lys(Boc)-OH and a BHQ2-
COOH on to the resin, respectively. After synthesis, the resin was sequentially washed with NMP, 
methanol and dichloromethane and dried in air. To perform peptide cleavage, the resin was stirred 
in 5 mL of TFA with 2.5% water and 2.5% triethylsilane at room temperature for 2 hr. The mixture 
was filtered to remove the resin. The supernatant was mixed with 10 mL of ethyl ether and 
evaporated in air flow to afford a dark blue solid. This solid was then dissolved in 10 mL of 
acetonitrile/methanol (1/1) and then mixed with HATU (0.2 M in acetonitrile, 2 mL), Fmoc-NH-
PEG4-COOH (0.4 M in acetonitrile, 1 mL) and DIEA (0.5 mL). The solution was stirred at room 
temperature for 3 hr. Subsequently, 10 mL of piperidine was added into the solution and mixed 
for 1 hr. The solvent was then removed under reduced pressure, resulting in a black solid. The 
solid was resuspended in 10 mL of water and then filtered. The supernatant was purified through 
HPLC to afford the product. (MOLDI-TOF, [M+H]+ calculated: 1612.853, observed: 1613.186). 
Antibody AF 647 conjugation  
Commercial antibodies were purified with protein A/G resins (Pierce) following manufacture’s 
protocols. The purified antibodies were buffer exchanged into pH 7.4 PBS buffer using Zeba 
protein desalting spin columns (Pierce).  Purified detection antibodies were reacted with AF647-
NHS following manufacture’s protocol (Life technologies). The degree of labeling was confirmed 
by absorption spectra. The labeled antibodies were stored in pH 7.4 PBS buffer with 0.02% NaN3 
as preservatives. The list of capture antibodies and their manufactures are shown in Table S3. 
DNA-encoded antibody library  
The DNA-encoded antibody library method was based on the literature (R. Bailey, et al., J. Am. 
Chem. Soc., 2007, 129, 1959-1967). 1 mg of S-HyNic and 1 mg of S-4FB were dissolved in 172 
uL and 50 uL of anhydrous DMF respectively. 100 ug of the purified antibody was reconstituted 
in PBS buffer at 1 mg/mL and 5 uL of the S-HyNic solution was added. In another vial, 50 uL of 
an ssDNA oligo solution (200 uM in PBS) was mixed with 12.5 uL of DMF, and 5 uL of the S-4FB 
solution was added. The antibody and the DNA solutions were incubated at room temperature for 
2 hr. The excess of the S-HyNic and S-4FB were removed through buffer exchanging into a pH 
6.0 citrate buffer using Zeba spin columns. The antibody and DNA solutions were then combined 
and incubated at room temperature for 2 hrs then at 4 oC overnight. The DNA-Antibody conjugate 
was purified through FPLC (GE, Pharmacia Superdex 200 gel filtration column) and concentrated 
by centrifugal filter (Millipore, Amicon Ultra-4, 10kD). The list of antibodies used in this work is 
shown in Table S2. 
DNA patterning on glass slides 
DNA barcode patterns are prepared using previously reported methods (J. Yu, et al., Annu. Rev. 
Anal. Chem., 2014, 7, 275-295). First a master mold was prepared using the SU8 2035 
photoresist. The mold was patterned with parallel channels at 10 um wide and 40 um high. A 
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Sylgard 184 (A:B=7:1) polymer mix was poured onto the mold, degassed under vacuum and then 
cured at 80 oC for 2 hours. The cured PDMS was released from the mold and bonded onto a poly-
L-lysine (PLL) coated glass slide (Thermo Scientific) to form enclosed channels. The number of 
analytes determines the number of the channels (11 channels in this study). The channels were 
flushed with a 0.1% PLL solution (Sigma Aldrich) and blown dry by air. Meanwhile, 5’-amine 
modified ssDNA was dissolved in a DMSO/H2O (2:3) solution at 300 uM and mixed with a 2 mM 
PBS solution of BS3 linker (Thermo Fisher) at 1:1 ratio (v/v). A library of freshly prepared DNA 
solutions were flown into different channels and the assembly was incubated at room temperature 
for 2 hours. The glass slide was then separated from the PDMS slab and washed with 0.02% 
SDS solution and water. Each patterned slide was validated using a solution of Cy3-labeled 
complementary DNA mixtures at one edge, and the fluorescence intensity of the barcodes were 
measured with an Axon GenPix 4400A scanner. The sequences of 5’-amine modified ssDNA are 
listed in Table S1, and the layout of the DNA patterning mold is shown in Fig S2. 
Preparation of single cell suspensions 
GBM 39 neurospheres were collected via centrifugation at 450 g for 5 min and the media was 
removed. The cells were then treated with 0.05% Tripsin/EDTA (Life Technologies) for 5 min at 
room temperature and the original media was added back to the pellet. The suspension was then 
centrifuged again and the supernatant was discarded. The cells are now disassociated as single 
cells and ready for tests.  
For SCBC measurements, the cells were resuspended in warm media with 10 ug/mL of Gluc-Bio 
at 6X105 cells/mL. The cells were incubated at 37 oC for 20 min and washed with cold PBS for 
three times. After washing, the cells were resuspended in serum-free, biotin-free media at a 
concentration of 1 M cells/mL and ready for loading. 
Cell culture and drug treatment 
GBM39 primary neurospheres were provided by Prof. C. David James (UCSF, San Francisco, 
U.S.A.) and cultured in Dulbecco’s Modified Eagle Media Nutrient Mix F-12 (DMEM/F12, 
Invitrogen) supplemented with B27 (Invitrogen), Glutamax (Invitrogen), Heparin (1μg/mL), 
Epidermal Growth Factor (EGF, 20ng/mL, Sigma), Fibroblast Growth Factor (FGF, 20ng/mL, 
Sigma) and 100 U/mL of penicillin and streptomycin (Gibco) in a humidified 5% CO2 (v/v) 
incubator, at 37 oC. For the drug treatment, 1 million cells were suspended in 10 mL of media 
and was cultured for several days to form neurosphere. Subsequently, the medium was 
changed to 10 mL of new media containing 1 μM erlotinib (ChemieTek). The cells were then 
treated for designated periods of time and processed for tests. 
Gluc-Bio / FDG kinetic measurements 
Aforementioned drug treated GBM 39 cells were dissociated into single cells and re-suspended 
in pre-warmed glucose-free, serum-free media (DMEM, Invitrogen) at a concentration of 105 
cells/mL (for FDG) or 2×105 cells/mL (for Gluc-Bio). Concentrated aqueous solution of Gluc-Bio 
or FDG was added to the cell suspension (final concentration: 10 μg/mL of Gluc-Bio, 4 uCi/mL 
of FDG). The cells were incubated at 37 oC for 10 min (Gluc-Bio) or 1 hr (FDG). At the end of 
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incubation, the cells were collected via centrifugation and washed three times with cold PBS 
buffer (2X original media volume). The resulting cells were either lysed for analyzing the Gluc-
Bio amount or re-suspended in PBS to measure the FDG content with a γ counter (1480 Wizard 
3; Perkin Elmer) . 
Fabrication of single cell barcode chip (SCBC) devices 
The SCBC devices consist of DNA barcode microarray glass slides and PDMS slabs that 
contain microfluidic circuits. The DNA barcode slides were prepared through microchannel-
guided flow patterning method Fig S2. The PDMS slabs were fabricated using a two-layer soft 
lithography approach. The flow layer was fabricated by spin-casting Sylgard 184 (A:B=20:1) 
polymer mix onto a SPR 220 positive photoresist mold (16 um in height) at 2000 rpm for 1 min. 
The control layer was molded from a SU8 2025 negative photoresist master (40 um in height) 
using Sylgard 184 (A:B=7:1) polymer mix. These two parts were cured at 80 oC for 20 min, and 
the control layer was aligned onto the flow layer. The two-layer device was thermally treated at 
80 oC (1.5 hr) and then released from the flow layer mold. After drilling the inlet/outlet holes from 
the PDMS, the slab was aligned onto the DNA barcode glass slides and treated at 80 oC (2 hr) 
to afford a fully assembled SCBC device. The layout of the device is illustrated in Fig S1. 
Operation of the SCBC devices 
1. Conversion of the DNA barcodes to capture antibody microarrays. The control 
valve 5 (Fig S1) was closed to separate the fluidic channels into upper and lower 
channels. The upper channels can be further compartmentalized into different 
operational units (microchambers), each of which was equipped with a full set of 
antibody barcode for cell trapping and analyte detection, while the lower ones were used 
as lysis buffer reservoir (Fig S1). A cocktail of DNA-encoded antibody conjugates in a 
BSA solution (1.5% in PBS) was flown into the upper channels and incubated at 37 oC 
for 1 hr to convert the DNA barcodes into antibody microarrays. The unbound 
conjugates were then washed off by 1X PBST (Cell Signaling, 0.05% Tween 20) and the 
channels were then blocked with a BSA (1% in 1X PBST) solution for 1 hr. 
2. Cell loading. The upper channels were briefly rinsed with cell culture medium to 
minimize perturbation to the cells. Simultaneously, GBM39 neurospheres were 
disassociated into single cells and incubated with Gluc-Bio. After washing to remove the 
excess Gluc-Bio, these single-cells were suspended in serum-free, biotin-free media at a 
concentration of 106 cells/mL. The suspension was loaded into the SCBC device and 
compartmentalized into 310 isolated microchambers with single cell or defined number 
of cells in each chamber. The cell loading step results in a random distribution of 
different numbers of cells in different chambers, the statistical distribution can be 
adjusted by varying the loading concentration and the flow speed. In our experiment 
setup, each chip typically has around 100 zero-cell chambers, 100 single cell chambers 
and 100 chambers with more than 2 cells. This distribution is critical in terms of signal 
background subtraction and validation. The extra cells were washed away by 1X PBST. 
The images of each chamber were recorded using a microscope-CCD camera and used 
for subsequent cell counting. 
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3. On-chip cell lysis. A cell lysis buffer mixture was introduced into the lower channels 
and the whole device was placed on ice. Valve 5 was opened for 15 min to allow the 
lysis buffer to diffuse into individual cell chambers under a positive pressure. After 
closing valve 5, the device was incubated on ice for another 15 min to complete the on-
chip cell lysis. The device was then incubated at room temperature with shaking for 2 hr 
to complete the capture of analytes by the antibody microarrays. After the incubation, the 
unbound cell lysate was quickly flushed away by 1X PBST. 
4. Applying the detection cocktail. A cocktail of Alexa Fluor 647-labeled detection 
antibodies as well as the Biotin-BHQ2 probe were prepared in a BSA solution (1% in 1X 
PBST) and flown into the device for 60 min to develop the analytes captured into 
fluorescence signal. 
5. Rinse and fluorescence readout. The channels were washed with 1X PBST for 30 
min. The barcode slide was then peeled off from the PDMS slab, washed sequentially 
with 1X PBS, 0.5X PBS and Millipore water, dried by a VWR Miniarray microcentrifuge, 
and scanned by an Axon GenePix 4400A at laser power 80% (635 nm) and 15% 
(532nm), and at 2.5 um/pixel resolution. Signals from two color channels were collected 
and digitized by the manufactures’ software. 
 
Generation of calibration curves 
 The standard calibration of metabolites were performed using SCBC devices under the same 
conditions described above, except that known concentrations of metabolite solutions were 
loaded into the device instead of the cells. The fluorescence signals from the resulted barcode 
slides were collected to generate the calibration curves (Fig 1d). These standard curves allow 
converting the relative fluorescence signal into copy number of analytes assayed, enabling 
absolute quantifications of the metabolites, under the condition that the same concentration of 
the competitors were employed in the experiments.  
 
Statistical analysis 
The SCBC dataset is an m × n matrix table, each row (m) of which represents a specific 
microchamber address with a defined number of single cells and each column (n) represents 
the abundance of a specific analyte in those microchambers. Pairwise comparison was 
performed through Mann-Whitney method. The correlation coefficients were directly calculated 
from the dataset using Spearman’s rank method. Bonferroni corrected p-value was used to 
define the statistical significance level for the entire panel and only significant ones were shown 
in the correlation network (Fig 3a). Agglomerative hierarchical clustering analysis was carried 
out by XLSTAT software (Addinsoft) on the single cell dataset. The proximity among single cell 
readouts was measured by the dissimilarity coefficients of Euclidian distance with Ward’s 
minimum variance method. The calculated dissimilarity coefficients were employed to quantify 
the functional heterogeneity of the cells. 
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Cell lysis buffer mixture recipe used in SCBC measurements 
400 uL of 10X cell lysis buffer (Cell Signaling), 20 uL of 100X protease/phosphatase inhibitor 
cocktail (Cell Signaling), 100 uL of 1.5% BSA/PBS, 3.3 uL cAMP-HRP (Genscript, 0.1 mg/mL), 
4.4 uL cGMP-HRP (Genscript, 0.1 mg/mL), 1 uL of Alexa Fluor 555-lebeled streptavidin (0.1 
mg/mL) and 0.5 uL GSH-AF647 (22.6 uM in PBS) 
Validation of the Gluc-Bio uptake 
GBM39 single cells were suspended in normal media (17.5 mM glucose) or high glucose media 
(25 mM glucose) at a concentration of 0.5 M cells/mL. These cells were incubated with 20 ug/mL 
of Gluc-Bio at 37 oC or 4 oC for 20 min. After incubation, cells were washed with cold PBS for 
three times and then lysed for quantifying the Gluc-Bio. The result is shown in Fig S5. 
Validation of the Gluc-Bio as a substrate for hexokinase 
In order to verify that Gluc-Bio is a substrate for hexokinase, a coupled enzyme kinetics 
measurement method was employed. Enzymes and substrate solutions from a glucose assay kit 
(Sigma-Aldrich) were used without purification. Fig S6a shows the two coupled enzymatic 
reactions. First, hexokinase converts glucose into glucose-6-phosphate, which consumes one 
equivalent of ATP. Then, the glucose-6-phosphate is converted to gluconate-6-phosphate by 
glucose-6-phosphate dehydrogenase (G6PDH). At the same time, this process converts NAD to 
NADH, which has a distinct absorption band at 340 nm. By continuously measuring the solution 
absorption, the kinetics of the first reaction can be indirectly monitored. If Gluc-Bio is a substrate 
for hexokinase, the product 2’-biotinyl-deoxyglucose-6-phosphate (Gluc-Bio-6P) cannot be further 
converted by G6PDH and therefore will not increase the NADH amount. This will result in a much 
slower generation of NADH. Fig S6b demonstrates that in the presence of Gluc-Bio, the 
generation of NADH is much slower than that of glucose alone. This proves that Gluc-Bio can 
bind to hexokinase and could be a substrate. However, this result cannot distinguish whether 
Gluc-Bio is a substrate or an inhibitor. In order to clarify this, another experiment was designed to 
prove that Gluc-Bio is a substrate. In this experiment, the amount of ATP was controlled to be 
much less than that of glucose. If Gluc-Bio is simply an inhibitor and cannot be converted by 
hexokinase, it will not consume the ATP pool in the solution, and the final amount of NADH will 
be the same as that of glucose alone. FigS6c shows that with the addition of Gluc-Bio, less NADH 
was generated. This proves that Gluc-Bio consumes ATP and therefore is a substrate for 
hexokinase.  
PET/CT methods: Mice kept warm under gas anesthesia (2% isoflurane) were injected 
intraperitoneally with 18F-FDG (20 µCi) and microPET scans were acquired for 10 minutes on the 
Genisys4 bench-top PET scanner (Sofie Biosciences). CT images were acquired the MicroCAT 
II CT system (Siemens) PET data are reconstructed into multiple frames using a statistical 
maximum a posteriori probability algorithm (MAP). CT (MicroCAT) images are at low dose 400 
µm resolution acquisition with 200 µm voxel size. PET and CT images are co-registered as 
previously described (Nathanson, D. A.; et al. J. Exp. Med. 2014, 211, 473-486).  
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MicroPET data analysis. Following MAP reconstruction, regions of interest (ROI) of were defined, 
both over tumors and the background, on the reconstructed images. ROI values were determined 
by normalization to the total radioactivity injected per body weight (%ID/g) to give the standardized 
uptake value (SUV).  
 
